Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive–compulsive disorder
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
The aim of this study was to investigate the efficacy and safety of ondansetron as an augmentative agent to fluvoxamine in the treatment of patients with obsessive-compulsive disorder (OCD). Forty-six men and women, aged 18-60 years, who fulfilled the diagnostic criteria of OCD on the basis of the DSM-IV-TR and had a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of at least 21 were recruited into the study. The patients randomly received either ondansetron (8 mg/day) or placebo for 8 weeks. All patients received fluvoxamine (100 mg/day) for the first 4 weeks, followed by 200 mg/day for the rest of the trial. The patients were assessed using the Y-BOCS and the adverse event checklists at baseline, and the second, fourth, sixth, and eighth week. Forty-four patients completed the study. The Y-BOCS total score as well as the Y-BOCS obsession subscale score and compulsion subscale score showed significantly greater reduction in the ondansetron group than in the placebo group. There was no significant difference in adverse events between the two groups. In this 8-week double-blind randomized-controlled trial, ondansetron showed significant beneficial effect as an augmentative agent with fluvoxamine in patients with moderate to severe OCD and it was generally well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, several smaller pilot trials showed that repeated dosing of ondansetron over multiple weeks reduced overall symptom severity in OCD [106–107] and TS [108], with potential utility as an augmentation strategy in SSRI-resistant OCD [106].”
From Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder (2021) · cites this paper as [106]
Citations
Cites
The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication
Ruscio, A. M., Stein, D. J., Chiu, W. T., & Kessler, R. C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.94 · Cited by 2,771 · cited 2×
“Introduction Obsessive–compulsive disorder (OCD) is a relatively common neuropsychiatric disorder, with an estimated lifetime prevalence of 1–3% in the general population (Karno et al., 1988; Sasson et al., 1997; Horwath and Weissman, 2000; Ruscio et al., 2010).”
BackgroundThe Yale-Brown Obsessive-Compulsive Scale: Measures of internal consistency
Kim, S. W., Dysken, M. W., Pheley, A. M., & Hoover, K. M. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90039-6 · Cited by 2,359
The Epidemiology of Obsessive-Compulsive Disorder in Five US Communities
Karno, M. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800360042006 · Cited by 1,351
Serotonin-dopamine interaction and its relevance to schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.466 · Cited by 823
Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635 · cited 1×
“Moreover, despite the fact that serotonin reuptake inhibitors (SRIs) are the mainstay of treatment and are used widely, almost 40–60% of patients fail to respond to initial treatment with these agents (Erzegovesi et al., 2001; Hollander et al., 2002; Bloch et al., 2006).”
BackgroundMcDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571 · cited 1×
“…that a hyperdopaminergic state plays an important role in the pathophysiology of both OCD and substance use disorders (Goodman et al., 1990; Mcdougle et al., 1994, 2000; Carmin et al., 2002; Repeated-measure analysis of variance for the effect of two treatments on the compulsion subscale…”
MethodMcDougle, C. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040046006 · Cited by 570
Mechanism of action of serotonin selective reuptake inhibitors
Stahl, S. M. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00221-3 · Cited by 540
Meneses, A. (1999) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(99)00067-6 · Cited by 475
A Review of the Efficacy of Selective Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder
Pigott, T. A., & Seay, S. M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0206 · Cited by 454
Cited by
Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment
Hirschtritt, M. E., Bloch, M. H., & Mathews, C. A. (2017) · JAMA · doi:10.1001/jama.2017.2200 · Cited by 493
Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder
Shephard, E., Stern, E. R., van den Heuvel, O. A., Costa, D. L. C., Batistuzzo, M. C., Godoy, P. B. G., Lopes, A. C., Brunoni, A. R., Hoexter, M. Q., Shavitt, R. G., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-01007-8 · Cited by 250
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
Del Casale, A., Sorice, S., Padovano, A., Simmaco, M., Ferracuti, S., Lamis, D. A., Rapinesi, C., Sani, G., Girardi, P., Kotzalidis, G. D., et al. (2019) · Current Neuropharmacology · doi:10.2174/1570159x16666180813155017 · Cited by 223
Paydary, K., Akamaloo, A., Ahmadipour, A., Pishgar, F., Emamzadehfard, S., & Akhondzadeh, S. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12370 · Cited by 116
Self-citationAlbert, U., Marazziti, D., Di Salvo, G., Solia, F., Rosso, G., & Maina, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666171222163645 · Cited by 90
Metadata
- Authors
- Heidari, M., Zarei, M., Hosseini, S. M. R., Taghvaei, R., Maleki, H., Tabrizi, M., Fallah, J., & Akhondzadeh, S.
- Affiliations
- Academic Center for Education, Culture and Research (IR)
- Roozbeh Hospital (IR)
- Tehran University of Medical Sciences (IR)
- Corresponding author
- Akhondzadeh, Shahin
- Venue
- International Clinical Psychopharmacology
- Published
- 2014-11
- Volume
- 29
- Issue
- 6
- Pages
- 344-350
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2042008286
- Cited by
- 48
- References
- 56
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 6 · 2018: 5 · 2017: 10 · 2016: 4 · 2015: 5
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Yale University
- Tehran University of Medical Sciences and Health Services
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- ondansetron, fluvoxamine, obsessive-compulsive disorder, drug augmentation, serotonin antagonists, Yale-Brown Obsessive Compulsive Scale, adverse events, drug tolerability
- MeSH terms
- Adolescent, Adult, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Placebos, Serotonin Antagonists, Fluvoxamine, Treatment Outcome, Ondansetron, Selective Serotonin Reuptake Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive–compulsive disorder. https://app.cochat.ai/papers/10.1097/yic.0000000000000043
- The paper
- Heidari, M., Zarei, M., Hosseini, S. M. R., Taghvaei, R., Maleki, H., Tabrizi, M., Fallah, J., & Akhondzadeh, S. (2014). Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive–compulsive disorder. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.